South Wales, Dec. 12 -- United Kingdom Intellectual Property Office (UKIPO) has registered trademark "CIS IMMUNE" on Dec. 2. The details about the trademark application no. UK00004304138 published in the journal no. 2025/050 (Dec. 12).

The University of Birmingham filed the trademark application for the below mentioned good(s)/service(s).

Class 1 : Chemical reagents for use in industry and science, including non-medical diagnostic testing.

Class 5 : Diagnostic reagents, assays and lateral flow test kits for medical use; assays and lateral flow test kits for research use; lateral flow and immunoassay tests for detecting infectious diseases or antibodies against infectious disease; lateral flow tests for detecting tetanus antibodies; lateral flow tests and immunoassays for detecting antibodies, antigens, and auto antibodies; chemical preparations for medical diagnostic purposes; pharmaceutical compositions for immunological research; diagnostic or research substances or reagents used in flow cytometry or other immune assays.

Class 9 : Electronic readers for diagnostic tests; software for interpreting lateral flow test results or other immunoassays; downloadable applications for managing diagnostic data.

Class 10 : Medical diagnostic devices; lateral flow testing apparatus or kits; point-of-care diagnostic instruments; laboratory testing kits, Tetanus antibody test kits; test kits for antibody, autoantibody, or antigen detection.

Class 42 : Scientific research and development in the field of diagnostic testing; research and development in immunology and vaccine response; laboratory services related to immunoassay platforms and sample processing and measurement; design and development of medical diagnostic and research technologies; consultancy and advisory services; validation of scientific methods or technologies relating to detecting antibodies, antigens and auto antibodies; scientific consultancy and field and laboratory testing services related to immune diagnostics; evaluation and reporting in scientific fields; design and execution of studies for immunological and diagnostic testing; evaluation and validation of immune response data and vaccine efficacy.

The original document can be viewed at: http://www.ipo.gov.uk/cgi-bin/redirect.cgi?type=tmj&link=6¶m1=UK00004304138

Disclaimer: Curated by HT Syndication.